Positive results were obtained in the phase III clinical trial of positive day clear PD-1 in the first-line advanced liver cancer in Androgenini

Paian puli monoantion (AK105) is a PD-1 monoantial developed and commercialized by Kangfang Bio and Zhengda Tianqing, which is expected to be a better clinically available PD-1 monoantial based on the complete removal of its Fc subjectivity and complement-mediated ability. Anantini, an innovative class 1 drug developed by Zhengda Tianqing and a multi-target small molecule tyrosine kinase inhibitor, was officially approved for listing on May 14, 2018 and successfully entered the Medicare Category B list in this year's health care negotiations.
results of this clinical study on hepatocellular carcinoma show that, as of November 2020, the objective remission rate (ORR) of the first-line treatment HCC for the combined low dose of amphrotinium (8 mg, two consecutive weeks, one week of suspension) was 31 .0%, with a disease control rate (DCR) of 82.8%, a medium progress-free lifetime (PFS) of 8.8 months, a six-month PFS rate of 63.2%, and a six-month OS rate of 93.2%.
from the Insight database () and in terms of security, the occurrence of level 3 and above adverse events (TRAEs) associated with Pa amprile or Androutini was 19.4%, and the rate of serious adverse events associated with Pample or Androtini was 6.5%.
the study, PaiAnpree combined with Therontinist combination to safely withstand encouraging anti-tumor activity as a first-line treatment for patients with advanced HCC.
, the findings support the exploration of higher doses of atrotinie in a joint with Paianpree.
is currently under way in a Phase III clinical trial (NCT04344158) of the first-line treatment of late-stage HCC with Pianpri combined with Arodini (10 mg for two consecutive weeks, one week of suspension).